Eris Lifesciences Board of Directors

Get the latest insights into the leadership at Eris Lifesciences. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Amit Bakshi Chairperson & Managing Director
Mr. Krishnakumar Vaidyanathan COO & Executive Director
Mr. Inderjeet Singh Negi Executive Director
Mr. Kaushal Shah Executive Director
Mr. Rajeev Dalal Independent Director
Mr. Sujesh Vasudevan Independent Director
Ms. Kalpana Unadkat Independent Director
Mr. Prashant Gupta Independent Director

Eris Lifesciences Share price

ERIS

1763.6

16.30 (-0.92%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:43 IST
BUYSELL
Today's High

1797.60

Today's Low

1745.50

52 Week Low

1097.20

52 Week High

1910.00

The current prices are delayed, login to your account for live prices

Eris Lifesciences FAQs

The board at Eris Lifesciences consists of experienced professionals, including Mr. Amit Bakshi , Mr. Krishnakumar Vaidyanathan , and others, overseeing the company’s strategic and corporate governance.

Directors at Eris Lifesciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Amit Bakshi is the current chairman at Eris Lifesciences.

Executive directors at Eris Lifesciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Eris Lifesciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Eris Lifesciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.